Adaptimmune Therapeutics Plc Revenue Growth Rates (ADAP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Adaptimmune Therapeutics Plc  (NASDAQ: ADAP)
 

ADAP's Revenue Growth by Quarter and Year

Adaptimmune Therapeutics Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADAP Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 13.68
1st Quarter March 7.29
FY 20.97

ADAPs Annual Revenue
Adaptimmune Therapeutics Plc's Revenue in the fiscal year 2024 $ 178.03 millions
Adaptimmune Therapeutics Plc's Revenue in the fiscal year 2023 $ 66.25 millions
Adaptimmune Therapeutics Plc's Revenue in the fiscal year 2022 $ 28.69 millions
Adaptimmune Therapeutics Plc's Revenue in the fiscal year 2021 $ 7.24 millions
Adaptimmune Therapeutics Plc's Revenue in the fiscal year 2020 $ 6.27 millions




ADAP Revenue second quarter 2025 Y/Y Growth Comment
Adaptimmune Therapeutics Plc reported drop in Revenue in the second quarter 2025 by -89.33% to $ 13.68 millions, from the same quarter in 2024.
The fall in the second quarter 2025 Adaptimmune Therapeutics Plc's Revenue compares unfavorably to the Company's average Revenue doubling of 266.92%.

Looking into second quarter 2025 results within Biotechnology & Pharmaceuticals industry 71 other companies have achieved higher Revenue growth. While Adaptimmune Therapeutics Plc' s Revenue meltdown of -89.33% ranks overall at the positon no. 4073 in the second quarter 2025.


ADAP Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 1300 % -98.01 % 531.15 %
3rd Quarter September - 458.74 % -0.14 % 510.83 %
2nd Quarter June -89.33 % 2399.61 % -13.05 % 75.6 %
1st Quarter March 28.35 % -88.07 % 1117.39 % 354.65 %
FY   - 195.34 % 110.11 % -

Financial Statements
Adaptimmune Therapeutics Plc's second quarter 2025 Revenue $ 13.68 millions ADAP's Income Statement
Adaptimmune Therapeutics Plc's second quarter 2024 Revenue $ 128.23 millions Quarterly ADAP's Income Statement


ADAP Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - -92.13 % -96.86 % 57.57 %
3rd Quarter September - -68.1 % 42.69 % 24.24 %
2nd Quarter June 87.61 % 2157.57 % -89.22 % 50.9 %
1st Quarter March 126.4 % 2369.57 % 312.12 % 113.66 %
FY (Year on Year)   - 195.34 % 110.11 % -


Back to ADAP Growth rate Comparisons >> Back to ADAP Growth rate Comparisons >>


Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #72
Healthcare Sector #603
Overall #4073

Revenue Y/Y Growth Statistics
High Average Low
2399.63 % 266.92 % -100 %
(Mar 31 2023)   (Dec 31 2019)
Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #72
Healthcare Sector #603
Overall #4073
Revenue Y/Y Growth Statistics
High Average Low
2399.63 % 266.92 % -100 %
(Mar 31 2023)   (Dec 31 2019)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Adaptimmune Therapeutics Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1745.46 % 145.23 % -100 %
(Jun 30 2024)  


ADAP's II. Quarter Q/Q Revenue Comment
Adaptimmune Therapeutics Plc achieved in the II. Quarter 2025 below company average Revenue jump of 87.61% quarter on quarter, to $ 13.68 millions.

Within Biotechnology & Pharmaceuticals industry 12 other companies have achieved higher Revenue quarter on quarter growth. While Adaptimmune Therapeutics Plc's Revenue growth quarter on quarter, overall rank is 122.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #43
Overall #122
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #43
Overall #122
Revenue Q/Q Growth Statistics
High Average Low
1745.46 % 145.23 % -100 %
(Jun 30 2024)  


ADAP's II. Quarter Q/Q Revenue Comment
Adaptimmune Therapeutics Plc achieved in the II. Quarter 2025 below company average Revenue jump of 87.61% quarter on quarter, to $ 13.68 millions.

Within Biotechnology & Pharmaceuticals industry 12 other companies have achieved higher Revenue quarter on quarter growth. While Adaptimmune Therapeutics Plc's Revenue growth quarter on quarter, overall rank is 122.


Adaptimmune Therapeutics Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)
Cumulative Revenue 12 Months Ending $ 65.09 $ 179.64 $ 178.03 $ 175.04 $ 141.46
Y / Y Revenue Growth (TTM) -53.99 % 878.53 % 195.34 % 144.47 % 97.53 %
Year on Year Revenue Growth Overall Ranking # 85 # 2642 # 60 # 34 # 11
Seqeuential Revenue Change (TTM) -63.77 % 0.9 % 1.71 % 23.74 % 670.56 %
Seq. Revenue Growth (TTM) Overall Ranking # 25 # 2637 # 2795 # 1687 # 1341


Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2025 Adaptimmune Therapeutics Plc reported a sharp drop in Revenue by -53.99% year on year, to $65 millions, compare to the 878.53% growth at Mar 31 2025.

Within the Healthcare sector 27 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 85, from total ranking in previous quarter at 2642.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 3
Healthcare Sector # 28
Overall # 85

Revenue TTM Y/Y Growth Statistics
High Average Low
633.18 %
 152.33 %
-164.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 10
S&P 500 # 25
Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2025 Adaptimmune Therapeutics Plc reported a sharp drop in Revenue by -53.99% year on year, to $65 millions, compare to the 878.53% growth at Mar 31 2025.

Within the Healthcare sector 27 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 85, from total ranking in previous quarter at 2642.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 3
Healthcare Sector # 28
Overall # 85

Revenue TTM Y/Y Growth Statistics
High Average Low
633.18 %
152.33 %
-164.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 10
S&P 500 # 25




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADAP's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue sharp drop for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Carlisle Companies Incorporated-0.08%$ -0.076 millions
Zimvie Inc -0.13%$ -0.128 millions
Community Health Systems Inc -0.22%$ -0.223 millions
Bruker Corporation-0.46%$ -0.462 millions
Integra Lifesciences Holdings Corp-0.61%$ -0.615 millions
Adapthealth Corp -0.70%$ -0.695 millions
Perrigo Company Plc-0.79%$ -0.789 millions
Organon and Co -0.81%$ -0.809 millions
Castle Biosciences Inc -0.94%$ -0.936 millions
Vaso Corporation-0.96%$ -0.963 millions
Profound Medical Corp -0.99%$ -0.985 millions
Capsovision Inc -1.13%$ -1.126 millions
Avantor Inc -1.14%$ -1.139 millions
Inspiremd Inc -1.35%$ -1.352 millions
Align Technology inc -1.51%$ -1.509 millions
Teladoc Health Inc -1.64%$ -1.641 millions
Supernus Pharmaceuticals inc -1.71%$ -1.706 millions
Encision Inc -1.73%$ -1.729 millions
Cytek Biosciences Inc -1.80%$ -1.796 millions
Merck and Co Inc -1.90%$ -1.899 millions
Bioventus Inc -1.98%$ -1.978 millions
Alkermes Plc -2.12%$ -2.123 millions
Anteris Technologies Global Corp -2.22%$ -2.215 millions
Surmodics Inc -2.55%$ -2.551 millions
Nrc Health-2.81%$ -2.807 millions
Rxsight Inc -3.09%$ -3.095 millions
Apyx Medical Corp-3.57%$ -3.567 millions
Quidelortho Corp-3.63%$ -3.626 millions
Lantheus Holdings Inc -4.00%$ -4.003 millions
Quipt Home Medical Corp -4.07%$ -4.065 millions


About Adaptimmune Therapeutics Plc Revenue Growth Rates (ADAP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Adaptimmune Therapeutics Plc (CIK 1621227).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-25-011307
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Adaptimmune Therapeutics Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.